09 July 2020
The European Patent Office (EPO) takes a different approach to the US PTO when considering obviousness/inventive step in antibody cases. In this webinar, Mathys & Squire partners Martin MacLean and Hazel Ford discuss the arguments that are most likely to be effective when addressing inventive step objections at the EPO, focusing on the field of antibodies.
Sign up to our mailing list to receive Mathys Matters, our monthly newsletter covering the latest IP news, industry insights, events and case law.
If you are interested in receiving quarterly newsletters relevant to our core sector groups - IT & engineering ('Inside Wires') and life sciences & chemistry ('Under the Microscope') - please select your preference(s) below:
Please select your practice area(s) of interest: